This study is recruiting. It focuses on bipolarity and currently lists participation information in the United States.
This study is looking at assess how safe and effective Icalcaprant is in treating adult participants with bipolar I or II disorder for people with Bipolarity I or Bipolarity II. Participants receive Icalcaprant or placebo and complete study visits and assessments. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.
The official record suggests in-person participation through a hospital, with sites including Sanro Clinical Research Group /ID# 279462 in Bryant, Advanced Research Center /ID# 272828 in Anaheim, and Collaborative Neuroscience Research - Garden Grove /ID# 271917. Participation appears to involve questionnaires, interviews, or regular check-ins about day-to-day experience. The main fit is usually matching the main diagnosis and meeting the main study requirements, while common reasons not to take part include active substance or alcohol problems that could affect the results and major medical issues that could make participation unsuitable. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordThis form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.
Taking part may help improve understanding of your condition.
It requires regular follow-up, often through questionnaires or interviews.
Requires travel, with in-person participation in United States.
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
This study is exploring medication or study treatment for people with bipolarity. Participants may complete study visits, assessments, or follow-up activities defined by the research team. It includes a comparison with placebo. Direct benefit is not guaranteed.
This study is sponsored by AbbVie. We could not clearly classify the sponsor type from the available data. Check the official source record to verify who is responsible for the study.
This study may involve medication or study treatment, study visits, and assessments. The time commitment is multiple visits or assessments. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.